Holen Sie sich die Stockscreener-App
4.00
0.50%
0.02
Handel nachbörslich:
4.00
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 - Yahoo Finance
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages - Defense World
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals announces inducement grants under Nasdaq Listing Rule - marketscreener.com
New X4 Pharmaceuticals hires get options at $3.70 a share - Stock Titan
Moving Averages: How much upside does X4 Pharmaceuticals Inc have2025 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
More Than 30,000 Prescribed Cholesterol Drugs Recalled Nationwide - The Healthy @Reader's Digest
Layoff Tracker: Gilead Continues California Cuts With 34 Laid Off - BioSpace
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
Exit Recap: Is X4 Pharmaceuticals Inc stock a value trapWeekly Stock Recap & AI Driven Stock Movement Reports - baoquankhu1.vn
Budget pitch: Pharma Inc seeks tax breaks for research and development - The Economic Times
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Jennison Associates LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug Breakouts: What is the long term forecast for X4 Pharmaceuticals Inc stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Lilly, Takeda targeted by legal strategy usually reserved for the mob - Pharma Voice
Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance
Quarterly Trades: Is AXSPRE attractive at current valuationWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st
Market Recap: What Wall Street predicts for X4 Pharmaceuticals Inc stock priceBear Alert & Accurate Buy Signal Alerts - Bộ Nội Vụ
Gains Report: How X4 Pharmaceuticals Inc stock reacts to inflationary pressuresM&A Rumor & Consistent Profit Trading Strategies - Bộ Nội Vụ
Aug Fed Impact: Can X4 Pharmaceuticals Inc stock deliver 10 annual returnsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - Bộ Nội Vụ
p-Chip Corporation, Choice One Rx, and RxERP Launch Precedent-Setting Trial Demonstrating Digital Traceability of Drug Supply Chains and Chain-of-Identity for DSCSA Compliance, Co-Sponsored by Avantor - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy - Yahoo Finance
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - BioSpace
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Why X4 Pharmaceuticals Inc. stock remains resilientQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
Why X4 Pharmaceuticals Inc. (48Q0) stock fits value portfoliosJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Улправда
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - Улправда
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
1.22%
2.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):